Literature DB >> 8817296

Superbugs: should antimicrobial resistance be included as a cost in economic evaluation?

J Coast1, R D Smith, M R Millar.   

Abstract

This paper argues that increasing resistance to antimicrobials is an important social externality that has not been captured at the level of economic appraisal. The paper explicitly considers reasons why the externality of antimicrobial resistance has not generally been included as a cost in economic evaluations comparing management strategies for infectious diseases. Four reasons are considered: first, that the absolute cost of antimicrobial resistance is too small to be worth including; second, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of time preference which makes the cost too small to be worth including; third, that there is an implicit discounting of the costs of antimicrobial resistance on the basis of uncertainty which makes the cost too small to be worth including; and fourth, that the costs are too difficult to measure. Although there does not appear to be methodological justification for excluding the costs of antimicrobial resistance, it seems likely that, because of the practical difficulties associated with measuring these costs, they will continue to be ignored. The paper concludes with a discussion of the applicability of standard policy responses used to deal with externalities in other areas of welfare economics.

Entities:  

Mesh:

Year:  1996        PMID: 8817296     DOI: 10.1002/(SICI)1099-1050(199605)5:3<217::AID-HEC200>3.0.CO;2-S

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  35 in total

1.  New-variant Creutzfeldt-Jacob disease.

Authors:  G Smith; R Charlton
Journal:  Br J Gen Pract       Date:  2000-08       Impact factor: 5.386

2.  Willingness to pay for dental fear treatment. Is supplying dental fear treatment socially beneficial?

Authors:  Bente Halvorsen; Tiril Willumsen
Journal:  Eur J Health Econ       Date:  2004-12

3.  Effects of extracts from Italian medicinal plants on planktonic growth, biofilm formation and adherence of methicillin-resistant Staphylococcus aureus.

Authors:  Cassandra L Quave; Lisa R W Plano; Traci Pantuso; Bradley C Bennett
Journal:  J Ethnopharmacol       Date:  2008-05-13       Impact factor: 4.360

4.  Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance.

Authors:  Raymond Oppong; Richard D Smith; Paul Little; Theo Verheij; Christopher C Butler; Herman Goossens; Samuel Coenen; Michael Moore; Joanna Coast
Journal:  Br J Gen Pract       Date:  2016-07-11       Impact factor: 5.386

Review 5.  Bacterial resistance: a sensitive issue complexity of the challenge and containment strategy in Europe.

Authors:  W T M Jansen; J T van der Bruggen; J Verhoef; A C Fluit
Journal:  Drug Resist Updat       Date:  2006-06-27       Impact factor: 18.500

6.  Detection of gyrA mutations associated with ciprofloxacin resistance in Neisseria gonorrhoeae by rapid and reliable pre-programmed short DNA sequencing.

Authors:  Baback Gharizadeh; Michael Akhras; Magnus Unemo; Bengt Wretlind; Pål Nyrén; Nader Pourmand
Journal:  Int J Antimicrob Agents       Date:  2005-11-07       Impact factor: 5.283

7.  De Novo Designed Amphipathic α-Helical Antimicrobial Peptides Incorporating Dab and Dap Residues on the Polar Face To Treat the Gram-Negative Pathogen, Acinetobacter baumannii.

Authors:  Colin T Mant; Ziqing Jiang; Lajos Gera; Tim Davis; Kirsten L Nelson; Shaun Bevers; Robert S Hodges
Journal:  J Med Chem       Date:  2019-03-21       Impact factor: 7.446

8.  Cost-effectiveness of point-of-care C-reactive protein testing to inform antibiotic prescribing decisions.

Authors:  Raymond Oppong; Mark Jit; Richard D Smith; Christopher C Butler; Hasse Melbye; Sigvard Mölstad; Joanna Coast
Journal:  Br J Gen Pract       Date:  2013-07       Impact factor: 5.386

9.  1,5-Anhydro-D-fructose: A natural antibiotic that inhibits the growth of gram-positive bacteria and microbial biofilm formation to prevent nosocomial infection.

Authors:  Xiaojie Meng; Ko-Ichi Kawahara; Hiroaki Miyanohara; Yasushi Yoshimoto; Kazuhiro Yoshinaga; Satoshi Noma; Kiyoshi Kikuchi; Yoko Morimoto; Takashi Ito; Yoko Oyama; Narimasa Yoshinaga; Binita Shrestha; Binita Chandan; Kentaro Mera; Ko-Ichi Tada; Naoki Miura; Yoshiko Ono; Kazunori Takenouchi; Ryuichi Maenosono; Tomoka Nagasato; Teruto Hashiguchi; Ikuro Maruyama
Journal:  Exp Ther Med       Date:  2011-04-01       Impact factor: 2.447

Review 10.  Applying economic principles to health care.

Authors:  R D Scott; S L Solomon; J E McGowan
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.